Business Wire

MA-ONPROCESS-TECHNOLOGY

30.9.2021 13:02:11 CEST | Business Wire | Press release

Share
OnProcess Launches OnProcess Agora™ a New Digital Platform that Improves the Performance, Efficiency and Sustainability of Service Supply Chains

OnProcess Technology, Inc. , a global pioneer powering the world’s circular service supply chains, announced today the general availability of its new cloud-based technology platform, OnProcess Agora™ along with Agora Recover™, an asset recovery solution that delivers new levels of digital customer experience. The OnProcess Agora platform, which hosts a suite of applications, communications and business intelligence tools underpinned by a proprietary data model, helps improve the management, efficiency and orchestration at every stage of the service-parts supply chain. The solution automates key after-sales processes and equips customers with a digital-first approach that results in greater financial, sustainability and customer service outcomes.

Today’s after-sale supply chain continues to be incredibly manual, siloed and complex. This makes orchestrating a circular supply chain – where manufacturers and sellers order, consume, return and refurbish used parts to cut down on costs, reduce waste and improve service – nearly impossible. OnProcess Agora™ overcomes this challenge by integrating the entire service supply chain into a single platform and automatically capturing and blending parts data, customer data and OnProcess proprietary data across the post-sale service lifecycle.

“The after-sale service supply chain has a direct and substantial impact on customer service, sustainability outcomes and the bottom line. Unfortunately, the typical service supply chain today is a web of disconnected, manual processes managed by siloed departments and systems,” said Oliver Lemanski, CEO of OnProcess. “That’s why we designed Agora, which gives our customers complete control and visibility across the service supply chain, and uniquely combines parts management data with data that focuses on the customer experience. The platform is a key enabler of our company’s vision to power the world’s circular service supply chains and puts sustainability and customer lifetime value at the heart of the everything-as-a-service economy.”

OnProcess’ AI-driven digital solution for asset recovery, Agora Recover™ , is the first application to be released on the OnProcess Agora™ platform. With sophisticated reporting capabilities, self-service portals and cloud-based integrations into almost any application or data source, Agora Recover supports the circular service supply chain by giving customers a holistic view of the parts recovery cycle. The resulting visibility and intelligence reduce unnecessary transportation costs and promotes sustainability by intelligently redirecting recovered parts according to value, demand and reusability.

“Agora Recover makes it easier to recover the inventory that matters most and provides new digital services for a more frictionless customer experience,” added Lemanski. “By providing real-time information to the right people, when and where they need it, helps teams recover parts faster, make better decisions, optimize operations, improve warranty recovery, reduce costs and emissions, and significantly improve customer satisfaction.”

To learn more about OnProcess Agora™ or Agora Recover™, or to request a demonstration, visit www.onprocess.com .

About OnProcess Technology, Inc.

OnProcess supplies technology and services that powers the world’s circular service supply chains. Providing managed services and digital transformation expertise that streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals, OnProcess is a trusted advisor to many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies.

Link:

ClickThru

Social Media:

https://www.facebook.com/OnProcessTechnologyInc/?fref=ts

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye